| Name | Title | Contact Details |
|---|---|---|
Anthony Rossomando |
Vice President of Technical Operations | Profile |
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
Octapharma is committed to promoting excellence in patient care and providing valuable information to the medical and patient community. This will help to better manage the treatment of disease and to improve patient safety and population health
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.
Nitrome Biosciences has discovered and identified a new class of enzymes.
MindMaze is pioneering a breakthrough computing platform that captures brain activity upon intent, creating a new operating system for computers - a brain O/S - with initial applications in the healthcare and gaming industries.